- Home
- IKT vs DERM Comparison
IKT vs DERM Comparison
Compare IKT & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKT
- DERM
- Stock Information
- Founded
- IKT 2008
- DERM 2014
- Country
- IKT United States
- DERM United States
- Employees
- IKT N/A
- DERM N/A
- Industry
- IKT Biotechnology: Pharmaceutical Preparations
- DERM Biotechnology: Pharmaceutical Preparations
- Sector
- IKT Health Care
- DERM Health Care
- Exchange
- IKT Nasdaq
- DERM Nasdaq
- Market Cap
- IKT 140.5M
- DERM 165.6M
- IPO Year
- IKT 2020
- DERM 2021
- Fundamental
- Price
- IKT $1.94
- DERM $7.41
- Analyst Decision
- IKT Buy
- DERM Strong Buy
- Analyst Count
- IKT 2
- DERM 1
- Target Price
- IKT $8.00
- DERM $9.00
- AVG Volume (30 Days)
- IKT 529.3K
- DERM 193.1K
- Earning Date
- IKT 08-13-2025
- DERM 08-11-2025
- Dividend Yield
- IKT N/A
- DERM N/A
- EPS Growth
- IKT N/A
- DERM N/A
- EPS
- IKT N/A
- DERM N/A
- Revenue
- IKT N/A
- DERM $56,243,000.00
- Revenue This Year
- IKT N/A
- DERM $28.99
- Revenue Next Year
- IKT N/A
- DERM $52.61
- P/E Ratio
- IKT N/A
- DERM N/A
- Revenue Growth
- IKT N/A
- DERM N/A
- 52 Week Low
- IKT $1.12
- DERM $3.54
- 52 Week High
- IKT $4.20
- DERM $8.25
- Technical
- Relative Strength Index (RSI)
- IKT 52.68
- DERM 58.55
- Support Level
- IKT $1.81
- DERM $6.78
- Resistance Level
- IKT $2.09
- DERM $7.34
- Average True Range (ATR)
- IKT 0.14
- DERM 0.38
- MACD
- IKT 0.02
- DERM 0.05
- Stochastic Oscillator
- IKT 71.70
- DERM 58.74
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.